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month p = 0.022, 9th month p = 0.008). CONCLUSIONS: Each
measure evaluates a different aspect of overall compliance. MPR
methodology, which measures the degree of prescription-ﬁlling
during treatment and does not factor in duration of treatment,
may be considered a surrogate measure for adherence. ELPTs 
are a pure measure of persistence, useful even in sub-optimally
adherent patients. PDCs are a composite measure of adherence
and persistence where the degree of prescription-ﬁlling is
reported quarterly in an attempt to describe patient behavior 
longitudinally.
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OBJECTIVES: In economic evaluation of health care pro-
grammes, productivity costs are often overestimated, because
compensation of lost work is neglected. This study tested the
conclusions of a small previous study (Severens et al. 1998)
which indicated that short-term work absence often is compen-
sated for during normal work hours, thereby leading to limited
productivity costs. METHODS: We studied work absence and
compensation of lost work in ﬁve different patient populations
(psoriasis, low back pain, chronic fatigue syndrome, rheumatoid
arthritis and persistent dyspepsia) and one employee population
(workers of a pharmaceutical company). RESULTS: this study
showed that only About 70–75% of lost work hours were com-
pensated by the absentee or colleagues during normal working
hours. Between 25–30% of the productivity costs as calculated
by the classical method remained, if productivity costs were only
calculated when extra efforts were needed. For 1 day absence
only in 17–19% of the cases work absence resulted in produc-
tivity costs were relevant, while this was 35%–39% for absence
of two weeks or longer. Measurement of the compensating mech-
anisms seemed to be valid, because of the large since the agree-
ment between the opinion of supervisors and their employees
whether compensation takes productivity costs. The measure-
ment of compensating mechanisms, seemed to be valid. Also, for
different occupations different compensating mechanisms were
reported in the expected direction. In our study populations,
Compensating mechanisms differed with occupational charac-
teristics, like part-time work, managerial work and shift work.
For example, higher educated workers more often compensate
for lost work themselves. CONCLUSIONS: Including compen-
sation reduces productivity costs due to absence from work to a
considerable extent. Nevertheless, we advise researchers to take
a broad range for correction, because for some compensation
mechanisms the consequences for productivity costs may vary
between settings.
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REVIEW OF PUBLISHED COST-UTILITY STUDIES IN CHILD
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OBJECTIVES: To critically appraise published cost-utility analy-
ses of interventions in child and adolescent health care in terms
of the methods used to estimate quality-adjusted life years
(QALYs). METHODS: A comprehensive search of computerised
databases (e.g. Medline, Embase) was undertaken to identify
cost-utility studies published prior to April 2004. Studies were
categorised according to the methods used to describe health
status, the valuation technique and source of preferences. The
methods were compared with the guidelines of the U.S. Panel on
Cost-effectiveness in Health and Medicine and the National
Institute for Clinical Excellence (NICE) in England and Wales
which recommend the use of a generic health status classiﬁca-
tion system (e.g. HUI, EQ-5D), a choice-based valuation method
(e.g. SG or TTO), and preferences of the general population.
RESULTS: Fifty-four studies were reviewed, of which 34 (63%)
were published in the latter 5 years. A generic health status 
classiﬁcation instrument was used in 22 (35%) cases; the remain-
der developed study speciﬁc health state descriptions or elicited
preferences directly from patients or proxies. In 7 cases (11%),
sources were unclear. Utility values were elicited by using choice-
based techniques in 28 cases (42%), either as tariffs for health
status classiﬁcation instruments (17 cases) or by directly valuing
health state descriptions or patient health (11 cases). Commu-
nity preferences were only used in 23 cases (37%). Four studies
aggregated QALYs for mother/child or family/child pairs without
giving any theoretical justiﬁcation. CONCLUSIONS: Although
the number of cost utility studies is increasing exponentially, 
the majority of studies did not adhere to standard recommen-
dations with little improvement over time. Further research is
warranted to develop appropriate methods to measure and value
child health beneﬁts within the QALY framework. In the interim,
an expert panel is needed to provide guidance for cost-utility
analysis of paediatric interventions to make studies more 
consistent.
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OBJECTIVE: Drug-eluting stents (DES) elute drugs that prevent
coronary restenosis after a percutaneous revascularization. The
cost of DES is quite high therefore imposing a relevant burden
to hospital and NHS budgets. Patients selection and reimburse-
ment policies need to be settled according to a large amount of
clinical (number and anatomy of revascularized vessels, diabetes,
unstable angina), economic (local cost of devices and procedures)
and organizational variables (adoption rate of different types of
DES and BMS, number of stent/procedure, shift from surgical to
DES revascularization). The resulting decision models are usually
blamed for high complexity but poor completeness and low
transparency. METHODS: Bayesian networks (BN) are close
acyclic graphs displaying value nodes, probability nodes and,
possibly, decision nodes (inﬂuence diagrams). We explored the
application of BN to policy selection for DES use, in both the
NHS and the hospital perspective. Three commercial softwares
were compared: Netica, TreeAgePro, HuginLite. Beta and
gamma distributions were used to represent the probability of
conditions/events and unit costs, respectively. Log-normal distri-
butions were used to model relative risks. RESULTS: BN mod-
eling of the DES problem was feasible with the three softwares
and required 35–40 nodes. We tested ﬁve types of restriction
policies to DES use, anchored to: 1) the presence of diabetes; 2)
the number of vessels to be revascularized; 3) the overall risk of
restenosis; 4) a cutoff adoption rate of DES; and 5) a cutoff
budget. We could verify that ﬂexibility, directness and trans-
parency varied among the softwares. Also software modalities to
manage uncertainty and to report the results had different
appeal. CONCLUSIONS: BN allows rapid and transparent esti-
mations of the local/speciﬁc economic impact of several differ-
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ent cost-containment policies, i.e. restriction for use of DES,
along with the uncertainty surrounding the estimate.
QUALITY OF LIFE I
QL1
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REPORTED OUTCOMES IN LIPODYSTROPHY (HIV/AIDS)
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OBJECTIVES: Lipodystrophy may greatly impairs quality of life
(QoL). Nevertheless, the recognition of the scientiﬁc value of
QoL and more broadly the patient’s perspective in evaluating
therapies is questioned. It may be useful to quantify the added
value of the patient’s perspective, using correlations between
patient-reported outcomes (PRO’s) and clinician-reported and
biological outcomes. METHODS: We performed a cross-
sectional survey in 143 HIV French outpatients with lipodystro-
phy. Clinical and demographic data were collected. Patients 
completed a new speciﬁc lipodystrophy questionnaire “Assess-
ment of Body Change and Distress” (ABCD), consisting of three
parts: signs of lipodystrophy (six items), global satisfaction (n =
1) and 20 items evaluating QoL. An HIV speciﬁc (MOS-HIV) 
and generic (SF-12) QoL questionnaires were also ﬁlled-in.
RESULTS: Mean age was 43 ± 10yrs (71% of men), and mean
duration of HAART was 4.5 ± 1.7yrs. ABCD QoL score is
weakly or no associated with viral load (r = 0.03), CD4 count
(r = 0.13) and CDC classiﬁcation (p = NS). Its correlation with
the clinician’s report of number of sites of lipodystrophy is weak
(r = 0.17). Correlations between different PRO’s are logically
higher. ABCD QoL score is more correlated with the patient’s
report of number of sites of lipodystrophy (r = 0.39) and with
satisfaction (r = 0.58). ABCD QoL score is correlated with health
distress and social dimensions of the MOS-HIV (r > 0.6) and
with mental component of the SF-12 (r = 0.65), but not with
physical dimensions of these questionnaires (r < 0.2). CON-
CLUSIONS: PRO’s are weakly correlated with biological
markers, and although overlapping, each one of PRO’s measures
a distinct concept. Clinicians cannot infer the QoL of their
patients neither from a viral load nor from a clinical exam. The
patient’s perspective is essential in medical decision making and
so it is with lipodystrophy.
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OBJECTIVES: To prospectively evaluate the health-related
quality of life of patients with Parkinson’s disease (PD) in
Germany over a 12 months observation period. METHODS:
The study included 145 patients with PD (mean age: 67.3 ± 9.6
years) in Germany. Patients were asked to complete the EQ-5D,
Par-kinson’s Disease Quality of life questionnaire (PDQL). 
and the Par-kinson’s Disease questionnaire-39 (PDQ-39). In
addition, the occurrence of depression and dementia were inves-
tigated using the Beck’s Depression Inventory (BDI) and the
Mini-Mental-State-Examination (MMSE). Evaluations were per-
formed at baseline, three, six and 12 months. Disease severity
was documented by the Uniﬁed Parkinson’s Disease Rating Scale
(UPDRS) and the Hoehn & Yahr (HY) scale. RESULTS: At base-
line mean VAS-value was 59.9 ± 18.0 and mean EQ-5D index
was 0.74 ± 0.25. HRQoL of patients suffering from dyskinesias
(47.5) were lower than in patients without dyskinesias (61.7). In
HY-stage I mean VAS was 72.8 ± 16.9 vs. HY V 45.7 ± 10.6. At
12 months the overall PDQ-39 score declined slightly from base-
line 29.4 ± 17.4 (n = 137) to 25.6 ± 16.2 (n = 128). Similar results
were found for the PDQL overall score (118.6 ± 27.5 (n = 87)
compared to 122.8 ± 26.1 (n = 72)) and the EQ-5D index (0.74
± 0.25 (n = 115) compared to 0.74 ± 0.25 (n = 115). No signif-
icant changes were found for the clinical scores (UPDRS and
Hoehn & Yahr scale) and the psychometric questionnaires
(MMSE and BDI). CONCLUSIONS: The PDQ-39, PDQL and
the EQ-5D are instruments delivering stable test results for PD
patients. There is no signiﬁcant change during the 12-months
abservation period in all used instruments. As this study will
have a follow-up up to three years a more detailed analysis of
time-dependent changes of HRQoL will be possible. Depression
and motor complications are the factors with the highest impact
on health-related quality of life in PD patients.
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QUALITY OF LIFE OF GASTROESOPHAGEL REFLUX DISEASE
PATIENTS
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OBJECTIVES: Gastroesophageal Reﬂux Disease is a chronic
condition whose symptoms cause great impairment on a patient’s
quality of life. Our aim was to evaluate GERD patients Health
Related Quality of Life (HRQoL) and its association to clinical
status. METHODS: A cross-sectional observational multicentre
cost of illness study was conducted in the urban area of Milan.
The study involved 317 patients (mean age 59 years, 58%
female) sequentially enrolled by 47 General Practitioners. Infor-
mation was collected investigating demographic, clinical, eco-
nomic and quality of life variables. To assess QoL in GERD
patients we used a generic (EuroQol) and a speciﬁc (Quality of
Life in Reﬂux and Dyspepsia, QOLRAD heartburn version)
questionnaire. We report on QoL data. RESULTS: A strong
impairment in the HRQoL was documented both with EQ-5D
and QOLRAD instruments. Patients reported an average value
of 64.4 in the EQ-VAS, signiﬁcantly lower compared to general
population. The EQ-proﬁle indicated that “pain/discomfort”
and “anxiety/depression” were the most impaired domains. We
converted the EQ-proﬁle in economic utility score by means of
values from UK and Catalonia. Using the UK conversion values
we had a utility mean score of 0.70 (±0.23), using the Catalonia
conversion values the mean score was 0.79 (±0.21). The EQ-VAS
value signiﬁcantly decreased with age, heartburn, epigastric pain,
odynophagia, globus sensation, relapse of symptoms and with
all the QOLRAD domains. The most impaired QOLRAD
domain was “food/drink problems”, the less one was “physi-
cal/social functioning” with a mean value of 4.95 and 5.74
respectively (one worst, seven best imaginable health state). The
internal consistency tested with Cronbach’s alpha was >0.8 for
all domains. Results with QOLRAD were conﬁrmed by those
with EQ-5D. CONCLUSIONS: This is the ﬁrst Italian study on
quality of life of GERD patients visited by GP’s, highlighting that
this disease signiﬁcantly impairs global patients’ HRQoL.
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